Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of BNT324 versus docetaxel plus prednisone/prednisolone in metastatic castration-resistant prostate cancer
CTR20262466Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of db-1311 in prostate cancer (PCa), sponsored by AbbVie Inc.. Started Aug 2026; status: active.
02
Drugs
db-1311
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20262466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262466.